449 research outputs found
Recommended from our members
A Primer on Quality Assurance and Performance Improvement for Interprofessional Chronic Kidney Disease Care: A Path to Joint Commission Certification.
Interprofessional care for chronic kidney disease facilitates the delivery of high quality, comprehensive care to a complex, at-risk population. Interprofessional care is resource intensive and requires a value proposition. Joint Commission certification is a voluntary process that improves patient outcomes, provides external validity to hospital administration and enhances visibility to patients and referring providers. This is a single-center, retrospective study describing quality assurance and performance improvement in chronic kidney disease, Joint Commission certification and quality outcomes. A total of 440 patients were included in the analysis. Thirteen quality indicators consisting of clinical and process of care indicators were developed and measured for a period of two years from 2009-2017. Significant improvements or at least persistently high performance were noted for key quality indicators such as blood pressure control (85%), estimation of cardiovascular risk (100%), measurement of hemoglobin A1c (98%), vaccination (93%), referrals for vascular access and transplantation (100%), placement of permanent dialysis access (61%), discussion of advanced directives (94%), online patient education (71%) and completion of office visit documentation (100%). High patient satisfaction scores (94-96%) are consistent with excellent quality of care provided
Prevalence of Microalbuminuria among Diabetic Patients in Usmanu Danfodiyo University Teaching Hospital, Sokoto
Diabetic nephropathy is a common phenomenon in patients with diabetes. Its prevalence risk factors have not been fully described in black African patients. This study determined the prevalence of microalbuminuria (mal) among diabetic patients in Usmanu Danfodiyo University Teaching Hospital (UDUTH) Sokoto. It involved 100 diabetics and 50 healthy controls. Mal was estimated by BCG-dye binding method, while fasting blood glucose (FBG) by glucose oxidation method. The prevalence of mal varied between males (24.3%) and females (16.6%). The duration of the disease ranged from < 5 years (42.0%) with 8(14.5%) having abnormal mal, (58%) >5 years with (31%) having abnormal mal, (30%) < 30 years having (17.1%) having abnormal mal and (70%) >30 years having (24%) with abnormal mal. The prevalence of mal was 22% (17% males and 5% females). FBG differed significantly (p<0.05) between patients (11.01±1.03mmol/l) and control subjects (4.38±0.07 mmol/l). Urinary albumin excretion was significantly higher in diabetics than in control (57.65±18.92 versus 24.16±1.48mg/24hrs respectively). Mal significantly (p<0.05) increased with duration of diagnosis of diabetes (108.6±14 versus 214.6±9.1 mg/24hrs in <5 years and >5years group respectively). Poor glycaemic control was the only modifiable predictor for the development of mal. Other non-modifiable risk factors related to progression of mal are sex and duration of disease. Early diagnosis of mal and aggressive glycaemic control is hereby recommended.Keywords: Microalbuminuria, Diabetic nephropathy, Fasting blood glucos
Antihypertensive Treatment in Diabetic Kidney Disease: The Need for a Patient-Centered Approach
Diabetic kidney disease affects up to forty percent of patients with diabetes during their lifespan. Prevention and treatment of diabetic kidney disease is currently based on optimal glucose and blood pressure control. Renin-angiotensin aldosterone inhibitors are considered the mainstay treatment for hypertension in diabetic patients, especially in the presence of albuminuria. Whether strict blood pressure reduction entails a favorable renal outcome also in non-albuminuric patients is at present unclear. Results of several clinical trials suggest that an overly aggressive blood pressure reduction, especially in the context of profound pharmacologic inhibition of the renin-angiotensin-aldosterone system may result in a paradoxical worsening of renal function. On the basis of this evidence, it is proposed that blood pressure reduction should be tailored in each individual patient according to renal phenotype
Reversibility of diabetic nephropathy
Obecnie główną przyczyną schyłkowej niewydolności nerek i konieczności leczenia nerkozastępczego jest nefropatia cukrzycowa. W wyniku przewlekłej hiperglikemii dochodzi do zmian czynnościowych i morfologicznych w nerkach, czemu towarzyszy stopniowe pogarszanie funkcji narządu. Wiąże się to ze wzrostem chorobowości i śmiertelności u chorych na cukrzycę. Wczesne rozpoznanie i leczenie nefropatii cukrzycowej pozwala na wdrożenie postępowania mającego nacelu odwrócenie lub spowolnienie postępu tej choroby. W niniejszej pracy przedstawiono możliwości odwrócenia zmian czynnościowych i morfologicznych w przebiegu nefropatii cukrzycowej u chorych na cukrzycę typu 1 i 2.Currently, diabetic nephropathy is the major cause ofend-stage renal disease and renal replacement therapy. Chronic hyperglycemia leads to functional and morphologic abnormalities and subsequent decline of kidney function. That is associated with increased morbidity and mortality. Early diagnosis of diabetic nephropathy allows to initiate treatment which can invert or inhibit progression of diabetic nephropathy. In this review we present methods that may lead to a reversion of functional and morphologic abnormalities in the course of diabetic nephropathy in patients with type 1 and type 2 diabetes
Renal Biopsy in Type 2 Diabetic Patients
The majority of diabetic patients with renal involvement are not biopsied. Studies evaluating histological findings in renal biopsies performed in diabetic patients have shown that approximately one third of the cases will show pure diabetic nephropathy, one third a non-diabetic condition and another third will show diabetic nephropathy with a superimposed disease. Early diagnosis of treatable non-diabetic diseases in diabetic patients is important to ameliorate renal prognosis. The publication of the International Consensus Document for the classification of type 1 and type 2 diabetes has provided common criteria for the classification of diabetic nephropathy and its utility to stratify risk for renal failure has already been demonstrated in different retrospective studies. The availability of new drugs with the potential to modify the natural history of diabetic nephropathy has raised the question whether renal biopsies may allow a better design of clinical trials aimed to delay the progression of chronic kidney disease in diabetic patients
Pasta consumption and connected dietary habits: Associations with glucose control, adiposity measures, and cardiovascular risk factors in people with type 2 diabetes—TOSCA.IT study
Background: Pasta is a refined carbohydrate with a low glycemic index. Whether pasta shares the metabolic advantages of other low glycemic index foods has not really been investigated. The aim of this study is to document, in people with type-2 diabetes, the consumption of pasta, the connected dietary habits, and the association with glucose control, measures of adiposity, and major cardiovascular risk factors. Methods: We studied 2562 participants. The dietary habits were assessed with the European Prospective Investigation into Cancer and Nutrition (EPIC) questionnaire. Sex-specific quartiles of pasta consumption were created in order to explore the study aims. Results: A higher pasta consumption was associated with a lower intake of proteins, total and saturated fat, cholesterol, added sugar, and fiber. Glucose control, body mass index, prevalence of obesity, and visceral obesity were not significantly different across the quartiles of pasta intake. No relation was found with LDL cholesterol and triglycerides, but there was an inverse relation with HDL-cholesterol. Systolic blood pressure increased with pasta consumption; but this relation was not confirmed after correction for confounders. Conclusions: In people with type-2 diabetes, the consumption of pasta, within the limits recommended for total carbohydrates intake, is not associated with worsening of glucose control, measures of adiposity, and major cardiovascular risk factors
Advances in the Renin-Angiotensin-Aldosterone System: Relevance to Diabetic Nephropathy
Hypertension is now recognized as a key contributory factor to the development and progression of kidney disease in both type 1 and type 2 diabetes. The renin angiotensin system (RAS) and its effector molecule angiotensin II, in particular, have a range of hemodynamic and nonhemodynamic effects that contribute not only to the development of hypertension, but also to renal disease. As a result, therapeutic inhibition of the RAS with angiotensin-converting enzyme inhibitors and/or selective angiotensin II type 1 receptor blockers has been proposed as a key strategy for reducing kidney damage beyond the expected effects one would observe with blood pressure reduction per se. Although the relationship between the RAS and the progression of diabetic renal disease has been known for many decades, recent advances have revealed a more complex paradigm with the discovery of a number of new components. Thus, further understanding of these new components of the renin angiotensin aldosterone system (RAAS), such as the angiotensin type 2 receptor subtype, angiotensin converting enzyme 2, and the recently cloned renin receptor, is likely to have therapeutic implications for disorders such as diabetic nephropathy, where interruption of the RAAS is widely used
Sodium-Glucose Cotransporter 2 Inhibitors and Kidney Outcomes:True Renoprotection, Loss of Muscle Mass or Both?
Inhibitors of sodium-glucose cotransporter 2 (SGLT2) have emerged as practice-changing treatments for patients with type 2 diabetes, reducing both the risk of cardiovascular events and kidney events. However, regarding the latter, caution is warranted, as these kidney endpoints are defined using glomerular filtration rate estimations based on creatinine, the non-enzymatic product of creatine residing in muscles. Creatinine-based estimations of the glomerular filtration rate are only valid if the treatment has no effect on changes in muscle mass over time. Yet, circumstantial evidence suggests that treatment with SGLT2 inhibitors does result in a loss of muscle mass, rendering serum creatinine-based kidney endpoints invalid. Currently, it cannot be excluded that the described renoprotective effect of SGLT2 inhibitors is in part or in whole the consequence of a loss of muscle mass. Post-hoc analyses of existing trials or new trials based on kidney function markers independent of muscle mass can provide more definitive answers on the proposed renoprotective effects of SGLT2 inhibitors
Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy - a meta-analysis
WSTĘP. Inhibitory konwertazy angiotensyny (ACEI)
i blokery receptora angiotensyny (ARB) zapobiegają
progresji nefropatii cukrzycowej (DN). Wyniki badań
sugerują, że połączenie układu renina-angiotensyna-aldosteron (RAAS) i czynników hamujących działa
addytywnie w procesie leczenia DN. Ponieważ badania
te obejmowały niewielkie grupy chorych, autorzy niniejszej pracy przeprowadzili metaanalizę
prób dotyczących leczenia skojarzonego DN.
METODY. Badania do metaanalizy wybrano na podstawie
baz danych MEDLINE, EMBASE, CINAHL i Cochrane.
Włączono wszystkie próby dotyczące skojarzonego
leczenia za pomocą ACEI i ARB. Głównym
punktem końcowym było dobowe wydalanie białka
z moczem, a dodatkowe punkty końcowe obejmowały: wartości ciśnienia tętniczego, stężenia potasu
we krwi i współczynnika przesączania kłębuszkowego
(GFR).
WYNIKI. W 10 włączonych do analizy badaniach
156 chorych otrzymało ACEI i ARB, a 159 jedynie ACEI. Większość badań trwało 8-12 tygodni. U osób
leczonych ACEI i ARB uzyskano zmniejszenie proteinurii
(p = 0,01), co wiązało się ze znaczną statystyczną heterogenicznością (p = 0,005). Terapia ACEI
i ARB była związana ze zmniejszeniem GFR [3,87 ml/min
(7,32-0,42); p = 0,03] i tendencją do wzrostu stężenia
kreatyniny w surowicy (6,86 umol/l 95% CI -0,76-13,73; p = 0,09). Stężenie potasu zwiększyło się
o 0,2 (0,08-0,32) mmol/l (p < 0,01) u chorych leczonych
ACEI i ARB. Skurczowe i rozkurczowe ciśnienie
krwi obniżyło się odpowiednio o 5,2 mm Hg (2,1-8,4) (p < 0,01) i 5,3 mm Hg (2,2-8,4) (p < 0,01).
WNIOSKI. Wyniki metaanalizy sugerują, że łączne stosowanie
ACEI + ARB w większym stopniu zmniejsza
24-godzinne wydalanie białka z moczem niż przyjmowanie
jedynie ACEI. Korzystne efekty terapii skojarzonej
są wynikiem niewielkiego wpływu leków na
GFR, stężenie kreatyniny i potasu w surowicy oraz
ciśnienie tętnicze. Rezultaty te należy interpretować
ostrożnie, ponieważ większość analizowanych badań charakteryzowała się krótkim czasem obserwacji,
a w kilku długoterminowych próbach (12 miesięcy) nie wykazano korzystnego wpływu leczenia.AIMS. Angiotensin-converting enzyme inhibitors
(ACEIs) and angiotensin receptor blockers (ARBs)
prevent the progression of diabetic nephropathy (DN).
Studies suggest that combination renin-angiotensin-aldosterone system (RAAS)-inhibiting therapy provides
additive benefit in DN. However, these studies
are small in size. We performed a meta-analysis of
studies investigating combination therapy for DN.
METHODS. Studies were identified through a search
of MEDLINE, EMBASE, CINAHL and the Cochrane
Database. All trials involving combined ACEI and ARB
for slowing progression of DN were included. The
primary end point was 24-
Blood pressure, serum potassium and glomerular
filtration rate (GFR) were secondary end points.
RESULTS. In the 10 included trials, 156 patients received
ACEI + ARB and 159 received ACEI only. Most
studies were 8–12 weeks in duration. Proteinuria was
reduced with ACEI + ARB (p = 0.01). This was associated with significant statistical heterogeneity (p = 0.005). ACEI + ARB was associated with a reduction
in GFR [3.87 ml/min (7.32-0.42); p = 0.03] and
a trend towards an increase in serum creatinine (6.86
umol/l 95% CI: -0.76-13.73; p = 0.09). Potassium was
increased by 0.2 (0.08-0.32) mmol/l (p < 0.01) with
ACEI + ARB. Systolic and diastolic blood pressure were
reduced by 5.2 (2.1-8.4) mm Hg (p < 0.01) and 5.3
(2.2-8.4) mm Hg (p < 0.01), respectively.
CONCLUSIONS. This meta-analysis suggests that ACEI +
+ ARB reduces 24-h proteinuria to a greater extent
than ACEI alone. This benefit is associated with small
effects on GFR, serum creatinine, potassium and blood
pressure. These results should be interpreted cautiously
as most of the included studies were of short
duration and the few long-term studies (12 months)
have not demonstrated benefi
- …